Income favourite GlaxoSmithKline (LSE: GSK) has finalised its impressively ambitious three-part deal with Swiss giant Novatis, and thus its shareholders can now look forward to a £4 billion cash return.
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.
Will You Get Your Share Of GlaxoSmithKline plc’s £4bn Special Dividend?
VIDEO: One Fool puts GlaxoSmithKline plc (LON:GSK) under the spotlight.
You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.